Published in Viral Immunol on February 01, 2013
Chikungunya vaccines in development. Hum Vaccin Immunother (2016) 0.76
Plant expression systems, a budding way to confront chikungunya and Zika in developing countries? F1000Res (2016) 0.75
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) (1956) 4.63
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Infectious diseases. Massive outbreak draws fresh attention to little-known virus. Science (2006) 2.90
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem? Lancet Infect Dis (2006) 2.61
A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J Gen Virol (2008) 2.05
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One (2009) 2.04
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol (Paris) (2007) 1.83
Chimeric alphavirus vaccine candidates for chikungunya. Vaccine (2008) 1.78
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res (2008) 1.64
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Pathogenomics of Culex quinquefasciatus and meta-analysis of infection responses to diverse pathogens. Science (2010) 1.58
Functional Sindbis virus replicative complexes are formed at the plasma membrane. J Virol (2010) 1.55
Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol (2010) 1.55
The 2005-2006 Chikungunya epidemic in the Indian Ocean. Vector Borne Zoonotic Dis (2006) 1.50
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35
Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine (2009) 1.32
Chikungunya virus infection. Med J Malaysia (2006) 1.21
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol (2012) 1.12
Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution. J Virol (2011) 1.10
Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. Gene Ther (2002) 1.07
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Chikungunya fever, Andaman and Nicobar Islands, India. Emerg Infect Dis (2007) 1.00
DNA drugs come of age. Sci Am (2010) 0.99
A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine (2011) 0.97
High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine (2010) 0.95
Current strategies and limitations of HIV vaccines. Curr Opin Investig Drugs (2010) 0.82
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev (2006) 2.77
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol (2005) 1.57
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36
Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg (2010) 1.35
HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem (2007) 1.27
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A (2013) 1.25
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. Viral Immunol (2011) 1.16
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol (2006) 1.12
HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol (2004) 1.11
Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 1.10
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine (2008) 1.06
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology (2005) 1.05
Seroprevalence of leptospirosis among high-risk population of Andaman Islands, India. Am J Trop Med Hyg (2006) 1.05
Outbreak of chikungunya fever, Dakshina Kannada District, South India, 2008. Am J Trop Med Hyg (2010) 1.04
Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines (2013) 1.04
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine (2011) 1.04
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03
Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology (2003) 1.03
Cytokines as adjuvants for improving anti-HIV responses. AIDS (2008) 1.03